This FAQ explains the use of Cost of Good Sold Analyses (COGS) and how they inform planning for product introduction.
Cost of Goods Sold (COGS) Analyses
Access to the Dapivirine Vaginal Ring: A timeline on progress
RINGing the Bell for Choice: Actions and Solutions on Dapivirine Ring Access
Thursday, September 22, 2022
Hear the latest updates from African advocates leading the advocacy for access to the dapivirine ring. Plus tune in for the Population Council’s plans for moving the ring forward on multiple fronts, from roll-out of the monthly ring to research around the 3-month ring and multipurpose ring.
Global Fund Investment Case: Seventh replenishment 2022 executive summary
The Global Fund’s analysis of the economic case for increased investment and commitment to its strategy pandemic preparedness and ending HIV, TB and malaria.
Global Fund Key Numbers and Messages
Key messages and numbers to advocate for full funding of the Global Fund.
ViiV’s Community Stakeholder Engagement Strategy for Low- and Middle-Income Countries (2022-2024)
ViiV’s 2022-2024 strategy for community stakeholder engagement in low and middle income countries pledges a commitment to Good Participatory Practice Guidelines and more.
Px Wire April-June 2022, Vol. 12, No. 1
Newly relaunched, PxWire is AVAC’s quarterly update covering the latest in the field of biomedical HIV prevention research and development, implementation and advocacy. Download for a quick look at where we are in HIV prevention.
A Plan for Accelerating Access and Introduction of Injectable CAB for PrEP (Summary)
AVAC published Translating Scientific Advance into Public Health Impact: A Plan for Accelerating Access and Introduction of Injectable CAB for PrEP to provide a comprehensive view of all the moving parts and identify specific priority actions and actors responsible for ensuring time is not wasted and opportunity not squandered in introducing injectable cabotegravir for PrEP. ViiV, policy makers, normative agencies, donors, program implementers, researchers, generic manufacturers, civil society, advocates and communities each have critical roles to play in the coming months, and this summary provides an overview of the plan.
COMPASS Africa Newsletter (July 2022)
Developed by the COMPASS MERL team, this issue offers SPARC stories and details on the MERL roadshow.
AVAC Comments to FDA in Support of PrEP Approval
Comments delivered to the FDA’s Antiviral Drugs Advisory Committee (AVDAC) Meeting by Mitchell Warren, Executive Director, AVAC.